Last €29.64 EUR
Change Today -0.221 / -0.74%
Volume 70.0
As of 3:20 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

roche holdings ltd-spons adr (RHO6) Snapshot

Open
€30.05
Previous Close
€29.86
Day High
€30.39
Day Low
€29.64
52 Week High
01/19/15 - €32.70
52 Week Low
02/6/14 - €25.14
Market Cap
205.5B
Average Volume 10 Days
465.6
EPS TTM
--
Shares Outstanding
5.6B
EX-Date
03/6/14
P/E TM
--
Dividend
€0.90
Dividend Yield
2.70%
Current Stock Chart for ROCHE HOLDINGS LTD-SPONS ADR (RHO6)

roche holdings ltd-spons adr (RHO6) Details

Roche Holding AG operates in the pharmaceuticals and diagnostics businesses in Switzerland, European Union, and internationally. It discovers, develops, and provides diagnostic and therapeutic products and services that enable patients and healthcare professionals in the detection, prevention, diagnosis, treatment, and treatment monitoring of diseases. The company provides pharmaceutical products for various therapeutic areas comprising oncology, virology, inflammation, metabolic disorders, and central nervous system. In addition, it offers a portfolio of diagnostics products, such as blood glucose meters for diabetes patients; point-of-care testing devices for use in doctors’ offices; high-throughput analyzers for hospitals and commercial diagnostic laboratories; and start-of-the-art instruments and reagents for life science research. The company has a collaboration agreement with Astrazeneca Plc to develop a plasma-based companion diagnostic test to support AZD9291, a drug candidate for treating non-small-cell lung cancer; and a collaboration agreement with AmorChem L.P. to discover novel small molecule disease-modifying therapy for the treatment of myotonic muscular dystrophy 1 or Steinert's disease. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.

Founded in 1896

roche holdings ltd-spons adr (RHO6) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: SFr.5.1M
Compensation as of Fiscal Year 2013.

roche holdings ltd-spons adr (RHO6) Key Developments

F. Hoffmann-La Roche Ltd and Foundation Medicine, Inc. Enter into Strategic Collaboration to Develop New Cancer Treatments

F. Hoffmann-La Roche Ltd. and Foundation Medicine, Inc. entered into a strategic collaboration to enhance the identification and development of novel treatment options for cancer patients. Understanding the comprehensive genomic profile of a cancer patient's disease will enable better personalized healthcare solutions to optimize treatment outcomes for patients. Under the terms of the R&D collaboration agreement, Roche is committing to R&D funding of potentially more than $150 million for a minimum of five years and will contribute its expertise and breadth in oncology. FMI will continue to operate independently and will contribute its experience in the development of comprehensive genomic profiling tests for oncology. The initial focus of the R&D collaboration will be on developing genomic profile tests for cancer immunotherapies and for continuous blood-based monitoring. Roche will be able to utilize FMI's proprietary molecular information platform to standardize clinical trial testing. This aspect of the relationship is designed to enable comparability of clinical trial results for R&D purposes, and ultimately in the clinic. The R&D collaboration and FMI's current and future tests are expected to deliver insights to support development of combination therapies, novel targets, more accurate patient population identification and inclusion in clinical trials, and next generation companion diagnostics. In addition to the R&D collaboration, both parties also agreed to a commercial collaboration agreement designed to broaden FMI's position across clinical and molecular information markets. Specifically, Roche will obtain rights ex-US (under the FMI brand) to existing FMI products, as well as to future co-developed products. In the US, Roche will engage its US medical education team in providing medical information to pathologists.

Roche Licenses Additional EGFR Pathway-Related Intellectual Property to QIAGEN

Roche announced that the company has entered into an agreement with QIAGEN that includes a provision of non-exclusive licenses to recently granted Roche patents pertaining to the detection of mutations in the EGFR pathway (including in the KRAS gene). Financial details were not disclosed. The licenses apply to testing products which detect these mutations using molecular techniques including PCR, next generation sequencing (NGS) and other applications to aid in identification of cancer patients eligible for treatment with certain tyrosine kinase inhibitors. The licenses can be applied to existing and future products.

Saudi Pharmaceutical Industries & Medical Appliances Corporation Signs Agreement with Roche to Manufacture, Sell Herceptin, Mabthera in Saudi Arabia

Saudi Pharmaceutical Industries & Medical Appliances Corporation announced that it signed an agreement with Roche's, under which SPIMACO will have the right to partially manufacture, and market and sell Roche's anti-cancer drugs MabThera (rituximab) and Herceptin (trastuzumab) in Saudi Arabia. The agreement is valid for a period of five years, with an option to be renewed. SPIMACO expects to start selling the drugs on the local market in the first half of 2015. The Saudi firm said it expects annual sales of some SAR 200 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RHO6:GR €29.64 EUR -0.221

RHO6 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bayer AG €127.81 EUR -1.75
Gilead Sciences Inc $104.83 USD +0.65
Merck & Co Inc $60.28 USD -1.81
Pfizer Inc $31.25 USD -0.58
Sanofi €82.00 EUR -0.26
View Industry Companies
 

Industry Analysis

RHO6

Industry Average

Valuation RHO6 Industry Range
Price/Earnings 24.8x
Price/Sales 4.6x
Price/Book 11.6x
Price/Cash Flow 20.2x
TEV/Sales 3.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROCHE HOLDINGS LTD-SPONS ADR, please visit www.roche.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.